TABLE 3.

Votes on “Other Benefits” that Are Not Adequately Captured in the Base-Case Cost-Effectiveness Model

Is it likely that gepants offers 1 or more of the following “other benefits” compared with over-the-counter therapies? (select all that apply)
This intervention will significantly reduce caregiver or broader family burden.	11/12
This intervention offers a novel mechanism of action or approach that will allow successful treatment of many patients for whom other available treatments have failed.	12/12
This intervention will have a significant impact on improving patients’ ability to return to work and/or their overall productivity	11/12
There are other important benefits or disadvantages that should have an important role in judgments of the value of this intervention (e.g., reduction of opioid misuse)	12/12
Is it likely that lasmiditan offers 1 or more of the following “other benefits” compared with over-the-counter therapies? (select all that apply)
This intervention will significantly reduce caregiver or broader family burden.	10/12
This intervention offers a novel mechanism of action or approach that will allow successful treatment of many patients for whom other available treatments have failed.	11/12
This intervention will have a significant impact on improving patients’ ability to return to work and/or their overall productivity	9/12
There are other important benefits or disadvantages that should have an important role in judgments of the value of this intervention (e.g., reduction of opioid misuse)	12/12
Is it likely that gepants offers 1 or more of the following “other benefits” compared with lasmiditan? (select all that apply
This intervention offers reduced complexity that will significantly improve patient outcomes.	9/12
There are other important benefits or disadvantages that should have an important role in judgments of the value of this intervention (e.g., reduction of opioid misuse)	12/12